Affordable Access

[N-acetylcystein in the therapy of chronic bronchitis].

Authors
  • Reichenberger, F
  • Tamm, M
Type
Published Article
Journal
Pneumologie (Stuttgart, Germany)
Publication Date
Dec 01, 2002
Volume
56
Issue
12
Pages
793–797
Identifiers
PMID: 12486618
Source
Medline
License
Unknown

Abstract

Chronic bronchitis (CB) shows an increasing global morbidity and mortality with major impact on socioeconomics. N-Acetylcysteine (NAC), previously used as a mucolytic compound in CB, has also antioxidative effects. Furthermore it influences intrabronchial bacterial colonisation. In a randomised pilot study of 24 patients (16-male, 8 female, mean age 66 +/- 10 years) with acute exacerbation of CB and positive bacterial culture in the sputum, the addition of twice daily 600 mg NAC to standard antibiotic therapy lead to a significantly higher bacterial eradication rate (70 % versus 36 %, p < 0.03). Clinical studies suggest that treatment with NAC has different effects in CB including a reduction of the number and duration of acute exacerbation episodes and possibly influences lung function. The improvement of symptoms and quality of life also has an impact on socio-economic costs. The use of NAC in CB as an antioxidative rather than a mucolytic compound should be considered. However, further placebo controlled studies are undergoing to definitively establish the role of NAC for the treatment of CB and COPD.

Report this publication

Statistics

Seen <100 times